Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCR4 IT
- Development stage
- Preclinical
- Lead developer
- Kyowa Kirin
- Modality
- Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intraperitoneal Injection
01
Overview
CCR4 IT is a diphtheria toxin-based recombinant immunotoxin developed as a potential therapeutic drug candidate for refractory and recurrent cutaneous T-cell lymphoma (CTCL). This immunotoxin is designed to specifically target cells that highly express the CC chemokine receptor 4 (CCR4), a cell-surface marker found on malignant T lymphocytes in CTCL. By binding to CCR4, the immunotoxin delivers a cytotoxic diphtheria toxin moiety directly to these cells, leading to their death. Preclinical studies have demonstrated its efficacy in targeting CCR4+ tumors and regulatory T cells (Tregs).
- Other names
- anti-human CCR4 immunotoxin
02
Targets
CCR4 (C-C Motif Chemokine Receptor 4)
Beyond the preview
Go deeper on CCR4 IT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCR4 IT.